Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
That's where ISHIN Premium comes in
The standard titration schedule spans 16 to 20 weeks, with dose increases every four weeks starting at 0.25 mg and advancing by 0.25 mg increments
When someone's sex drive is low, it can hurt their quality of life
In Mondays ruling, the judge did grant Mochi Healths request to dismiss Lillys civil conspiracy claim because, she said, the amended complaint does not include allegations supporting a plausible inference of an agreement to a common plan among Mochi Health, the Mochi Medical defendants, and Aequita Pharmacy